PROT Proteonomix Inc (CE)

Dear Shareholders:

This has been a momentous year for your Company. During the past several years we have asserted that our business lines would move forward in both the cosmetic area via our Proteoderm subsidiary and in the biopharmaceutical lines, most recently our UMK-121 technology.

Earlier this month the Company announced that it had entered into an agreement with a leading University ("The University") to conduct a Clinical Study entitled "UMK-121 in Patients with Liver Disease." Under the agreement The Company and The University agreed to conduct a clinical study entitled UMK-121 in Patients with Liver Disease. The University will pay expenses associated with this clinical study and the Company shall contribute $105,000 to assist with the clinical study. The University was most generous in assuming the vast majority of the costs associated with the clinical study. The Company believes that the University's action demonstrates that the University has a high degree of confidence in the potential of UMK-121.

The Company has previously described the terms of the agreement to license and develop and the patent application of the UMK 121 technology. This first clinical trial will be in ESLD ("End Stage Liver Disease") patients. The Company hopes to provide information about the clinical study in the upcoming weeks and months. In addition to ESLD we also believe that UMK-121 may have applications to the amelioration of disease processes in other organs, such as the kidneys and the heart. Further clinical studies will be required before moving UMK-121 to commercialization.

Yet another major achievement was made by the Company in early November when the Cosmetic Ingredients Review Board ("CIR") approved and assigned an INCI nomenclature to its innovative Matrix NC-138 Cosmeceutical product, a necessary final step prior to manufacturing and commercialization of cosmetic products in the United States. The approval of the CIR and its issuance of an INCI name to our Matrix NC-138 is a significant and momentous occasion. We have now demonstrated that we are committed to develop and deliver to the market safe and innovative products. The issuance of the INCI name will allow the company to move forward with commercialization of our cosmeceutical product, Proteoderm NC-138 in the USA.

Proteoderm, Inc. has already developed a line of anti-aging skin care cosmetics based on its research with stem cell derivatives. We are the first company to use a matrix of proteins ("Matrix NC-138") originally discovered in non-embryonic stem cells, to harness the anti-aging potential in Cosmeceutical products.

Our plan to market the Proteoderm products centers on partnering with other cosmetic manufacturers. This partnering process has already been greatly enhanced by the issuance of the INCI name. Based in Washington, D.C., the Personal Care Product Council ("PCPC") has funded the Cosmetic Ingredient Review ("CIR") Expert Panel as an independent, nonprofit panel of scientists and physicians established in 1976 to assess the safety of ingredients used in cosmetics in the U.S. with the support of the U.S. Food and Drug Administration and the Consumer Federation of America in an open, unbiased, and expert manner, and to publish the results in the peer-reviewed scientific literature. The CIR mission is to review and assess the safety of ingredients used in cosmetics in an open, unbiased, and expert manner, and to publish the results in the peer-reviewed scientific literature. Upon conclusion of its review the CIR issues an International Nomenclature of Cosmetic Ingredients ("INCI") name to the ingredient. The PCPC does not regulate but provides information on national and international regulation. We presently adhere to the Personal Care Products Council Consumer Commitment Code, including filing timely reports with the FDA regarding manufacturing and ingredient usage.

The Company also engaged the services of Gilford Securities Inc. in July to act as the Company's investment banking adviser for the purposes of assisting and advising the Company on enhancing shareholder value.

In summary, we have started to deliver on the promise of our technologies and expect that in the near future we will have confirmation via the human clinical study of the safety and perhaps even the efficacy of our UMK-121. We also anticipate making substantial progress in moving our Proteoderm NC-138 into commercial use during 2012.

On behalf of the Board of Directors Of Proteonomix, Inc.

/s/ Michael Cohen

Michael Cohen Chairman, Board of Directors

Forward-looking statements:

Certain statements contained herein are "forward-looking statements" (as defined in the Private Securities Litigation Reform Act of 1995). Proteonomix, Inc. cautions that statements made in this press release constitute forward-looking statements and makes no guarantee of future performance. Actual results or developments may differ materially from projections. Forward-looking statements are based on estimates and opinions of management at the time statements are made.

Add to Digg Bookmark with del.icio.us Add to Newsvine

Contact: Proteonomix, Inc. Michael Cohen CEO Phone: +1-973-544-6116 Email: Email Contact

Grafico Azioni Proteonomix (CE) (USOTC:PROT)
Storico
Da Gen 2025 a Feb 2025

Grafico Azioni Proteonomix (CE) (USOTC:PROT)
Storico
Da Feb 2024 a Feb 2025